Related Experiment Video

Updated: Aug 30, 2026

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

Progress in pharmacotherapy of thrombosis

Krzysztof Labuzek1, Robert Krysiak, Bogusław Okopien

  • 1Department of Clinical Pharmacology, Medical University of Silesia, PL 40-752 Katowice, Medyków 18, Poland. lobuzek@rubikon.pl

Polish Journal of Pharmacology
|October 29, 2003
PubMed

Insights

New therapies are being developed to address hemostatic disorders that cause dangerous blood clots. These novel agents aim to improve safety and efficacy in preventing and treating thromboembolic diseases.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Background:

  • Hemostatic disorders, characterized by excessive coagulation and impaired fibrinolysis, significantly increase the risk of life-threatening cardiovascular diseases like myocardial infarction and stroke.
  • These conditions are major contributors to morbidity and mortality in modern societies.
  • Current antithrombotic therapies present challenges, including adverse events, the need for monitoring, and inconvenient administration routes, driving the search for better treatments.

Purpose of the Study:

  • To review emerging therapeutic agents for hemostatic disorders currently in experimental and clinical investigation.
  • To discuss the potential future applications of these novel agents in managing thromboembolic diseases.

Main Methods:

  • Literature review of experimental and clinical studies on novel antithrombotic agents.
  • Analysis of agents targeting various pathways of coagulation and platelet activation.

Main Results:

  • Several classes of novel agents are under investigation, including prostanoids, nitroaspirin, GP IIb/IIIa receptor antagonists, thienopyridine derivatives, collagen-GPVI blockers, von Willebrand factor-GPIb-IX blockers, direct thrombin inhibitors, thrombin-platelet interaction inhibitors, factor VII inhibitors, and tissue factor-factor VII contact blockers.
  • These agents represent diverse mechanisms to modulate hemostasis and prevent thrombosis.

Conclusions:

  • Novel therapeutic agents show promise for the future prevention and treatment of thromboembolic diseases.
  • These agents may offer improved safety and efficacy profiles compared to existing therapies, addressing limitations of current treatments.

More Related Videos

Tracking Fibrinolysis of Chandler Loop-Formed Whole Blood Clots Under Shear Flow in An In-Vitro Thrombolysis Model06:16

Tracking Fibrinolysis of Chandler Loop-Formed Whole Blood Clots Under Shear Flow in An In-Vitro Thrombolysis Model

Published on: April 19, 2024

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...